Expert Opinion on Drug Safety

Carbonic anhydrase inhibitors (CAIs) have been a particularly hot topic recently, with a comprehensive review of the safety aspects associated with these drugs when used to treat different diseases published in Expert Opinion on Drug Safety in the April issue.ÿ

Welcome to this month?s Toxicology and Drug Metabolism newsletter.

Below you will find the latest published articles across all of Informa Healthcare?s Toxicology and Drug Metabolism journals.

This month our Editor in Chief, Prof. McIntyre, has chosen Christen and Chew?s review article considering whether long-term aspirin use can increase the risk of developing neovascular age-related macular degeneration. The full article can be accessed for free via the link included in this story.

A list of the ?Top 15 Drug Launch Superstars? was recently put together by Fierce Pharma. The Expert Collection has papers covering each of these drugs. The drugs on the list have all been successfully launched and approved and cover a range of indications

This week,ÿExpert Opinion on Drug Safetyÿhas provided compelling comment on the opioid-based painkiller debate with aÿfreeÿeditorial ?Painful decision-making at FDA?.

The editor’s pick from Professor Roger McIntyre for the March issue of Expert Opinion on Drug Safety is an evaluation by Professor Fabrizio Stocchi et al.ÿof ropinirole prolonged release therapy for Parkinson’s disease.

This month in Expert Opinion, treatments for pulmonary arterial hypertension are considered. We cover drugs that are established, recently approved and in phase III trials as well as evaluating the management of the condition in patients with congenital heart disease.

The Editor’s pick from Prof Roger McIntyre (University of Toronto, MD., FRCPC, Canada) for the Febuary issue of Expert Opinion on Drug Safety is ‘Incretin-mimetics associated pancreatitis: evidence from the spontaneous adverse drug reactions reporting in Italy’. This article comes from Marcello Delfino et al. (Department of Pharmacy, Ferrara, Italy).

The Editor’s pick from Prof Roger McIntyre (University of Toronto, MD., FRCPC, Canada) for the January issue of Expert Opinion on Drug Safety is ‘Idiosyncratic drug-induced liver injury: an update on the 2007 overview’. This article comes from S Hyder Hussaini and Elizabeth Anne Farrington (Hepatology Unit, Royal Cornwall Hospital, UK), click the link above to read more…

The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!

This week in the Expert Opinion journals we look at therapeutic targets and methods of targeted therapy from different points of view and stages of drug development.

Welcome to the November issue of the Toxicology and Drug Metabolism newsletter.

This month, we are pleased to offer you FREE access to 3 of the top downloaded articles from our Toxicology and Drug Metabolism journals

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis from Andre Scheen is our Editor’s pick for the July issue of EODS from Editor in Chief Roger McIntyre.

Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) play an increasing role in the management of type 2 diabetes, offering significant advantages over other agents which act by lowering glucose levels and have a potential association with increased risk of acute pancreatitis.

Welcome to the July issue of the Toxicology and Drug Metabolism newsletter.

This month, we are pleased to offer you FREE access to 3 of the top downloaded articles from our Toxicology and Drug Metabolism journals

Expert Opinion on Investigational Drugs would like to present a special issue dedicated to protein kinase inhibitors. These small molecules have potential to be active therapies in a wide variety of indications, from oncology through to neurology and beyond. Along with Guest Editor Tomi Sawyer, we explore some of the interesting drugs which fall into this class in this special issue of EOID.

In the May issue of the journal, Roger McIntyre (Editor-in-Chief) has selected the highly important issue of drug interactions among oral antineoplastic agents, as the Editor?s pick of the month.

We have recently published two highly viewed drug evaluations on the fixed-combination drug of linagliptin and metformin (also known as Jentadueto?).

Dr Kallala and colleagues explore the interesting effects of nicotine on bone, in this month?s Editor?s pick for the journal.

Saxagliptin overview: special focus on safety and adverse effects by Shamsa Ali & Vivian Fonseca is our editorial highlight of the EODS Janaury issue.

In the September issue of EODS, Dr Abraham and Dr MacDonald discuss the clinical safety of biosimilar recombinant human erythropoietins.

In this month?s issue of Expert Opinion on Drug Safety, Dr Catherine Kelly and co-authors review the effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.

The treatment of cancer is often complex, requiring various modes of therapy such as chemotherapy, radiotherapy and surgery. While traditional chemotherapeutic drugs aim to kill rapidly dividing cancer cells, they also kill normal cells resulting in many terrible adverse effects. Newer drugs aim to stop cancer growth by targeting specific molecules or antibodies and should, in theory, be less toxic to normal cells. Featuring an introductory editorial by Dr. Mario Lacouture, this supplement includes articles by experts in the field that focus on the safety of conventional and upcoming anticancer treatments, as well as the role of translational research and patient adherence in cancer drug safety.

Informa Healthcare?s recently launched CMEcast service announced today that its first four educational courses have received official approval from the European Board for Accreditation in Cardiology (EBAC) as EBAC Accredited Educational Programmes.

August 31, 2011 ? New York, NY ? Targeted Media, Inc., a Time Inc. company, has named Informa Healthcare Communications as their exclusive sales agent for ?The Educated Patient? series and pharma-sponsored magazine subscriptions in Europe. This builds upon their existing partnership in the US, where Informa Healthcare Communications provides content and creative direction for the series. Informa Healthcare Communications, a division of the global STM publisher Informa Healthcare, produces medical content tailored to both physicians and patients.